PARIS, Dec. 17, 2018 /PRNewswire/ -- Making its second appearance at CES, the world's leading technology event, on 8-11 January 2019 at Las Vegas, the Grenoble-based firm Diabeloop, invited by the CEA, will present its plan to adapt its machine-learning adult diabetes management system to children.
Full release to be downloaded here.
At CEA Tech Village in Eureka Park, Sands Expo
A pioneering system born of cutting-edge R&D serving Type 1 diabetes patients
Since 2015 Diabeloop and its R&D partner, CEA-Leti, have striven to transform the lives of people with Type 1 diabetes and their loved ones.
The solution developed by Diabeloop is an integrated closed-loop insulin delivery system made up of three devices: a continuous glucose monitor (CGM), a patch insulin pump and a handset terminal hosting the algorithms developed by Diabeloop and acting as a user interface with the system.
These algorithms predict blood sugar levels and instruct the pump to automatically deliver insulin doses.
The result of extensive consultations with patients, doctors, engineers and software developers, this disruptive innovation will transform the lives of patients, relieving them of many of the daily treatment decisions they have to make.
In adapting its DBLG1 automated insulin delivery system for adults (which in November 2018 received the CE marking) to children, Diabeloop wants to boost pediatric care and improve the short-term quality of life and overall longevity of children while relieving their loved ones of the stress of managing the disease on a daily basis.
At CES 2019, Diabeloop will present its innovative R&D-intensive system developed with and for children and their loved ones. Customizable and adjustable to every child's physiology and pace of life with several functionalities and made to fit every body type
Clinical trials with children are set to begin in Belgium and France in 2019.
New financing round
In November 2018 Diabeloop launched a second round of financing to support its ambitious R&D objectives and the international rollout of its DBLG1 system for adults.
Founded: in 2015 in Grenoble by Erik Huneker and Dr Charpentier. Diabeloop and CEA-Leti work together at a shared research laboratory to speed up the development of the system. Marc Julien and Erik Huneker are the firm's joint CEOs.
Financed: via €13.5 million raised in equity and debt in Jun-Aug 2017 with a second round of financing currently under way.
CE marking for DBLG1 for adults: obtained in November 2018.